ORIGINAL RESEARCH article
Front. Vet. Sci.
Sec. Comparative and Clinical Medicine
Volume 12 - 2025 | doi: 10.3389/fvets.2025.1635504
Efficacy of Yang Yin Sheng Xue Formula against Canine Lymphoma Chemotherapy-induced Myelosuppression
Provisionally accepted
- 1China Agricultural University, Beijing, China
- 2Chi University, California, United States
- 3China Agricultural University Veterinary Teaching Hospital, Beijing, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Lymphoma is a prevalent malignant tumor in canines, with chemotherapy as the primary treatment approach. However, chemotherapy indiscriminately targets all rapidly dividing cells, including normal hematopoietic cells, leading to myelosuppression. Recent veterinary practices still lack standardized and effective management strategies for myelosuppression. This study aimed to evaluate a novel treatment strategy, utilizing the Yang Yin Sheng Xue formula (YYSXF), to alleviate chemotherapy-induced myelosuppression in canines with lymphoma. In the laboratory research phase, a mouse myelosuppression model was established by intraperitoneal (i.p.) injection of cyclophosphamide (CP, 350 mg/kg). Blood cell counts were conducted following treatment with different concentrations of YYSXF. The number of bone marrow nucleated cells (BMNCs), the proportion of bone marrow hematopoietic stem cells (HSCs), and the apoptosis percentage of bone marrow cells (BMCs) were quantified. PI staining was performed to investigate YYSXF's effect on cell cycle progression in the S and G2/M phases of BMCs. Histopathological changes in sternum bone marrow were examined through pathological sections. The outcomes of multicentric lymphoma in 11 canines treated with either CHOP chemotherapy alone or in combination with YYSXF were assessed between April 2021 and April 2022. YYSXF was administered alongside CHOP chemotherapy (Test group, n = 5) to monitor blood cell parameter reduction, and compared with canines receiving only CHOP chemotherapy (Control group, n = 6) to evaluate YYSXF's efficacy. YYSXF treatment improved peripheral red blood cells (RBCs), white blood cells (WBCs), neutrophils (NEUTs), and platelets (PLTs), while reducing apoptosis and promoting cell cycle progression in bone marrow cells (BMCs) in myelosuppressed mice, however, validation in larger cohorts remains necessary. YYSXF also increased BMNC counts and the percentage of HSCs in BMCs, alleviating reductions in hematopoietic cell counts and fat vacuolation in the bone marrow. In the clinical phase, a decrease in complete blood count (CBC) indicators was observed after the eighth chemotherapy cycle in multicentric lymphoma canines, significantly delaying the onset of chemotherapy-induced reductions (P < 0.05) compared to the Control Group (third chemotherapy cycle). These findings suggest the potential efficacy of YYSXF in supporting bone marrow hematopoiesis in mice, with further validation in canine models needed before clinical application.
Keywords: myelosuppression, Yang Yin Sheng Xue formula, chemotherapy, canine, adverse effects
Received: 26 May 2025; Accepted: 18 Jul 2025.
Copyright: © 2025 Pan, Sun, Shiau, Xie, Jun and Jiahao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Dong Jun, China Agricultural University Veterinary Teaching Hospital, Beijing, China
Lin Jiahao, China Agricultural University, Beijing, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.